These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 34626563

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
    Lamarca A, Barriuso J, McNamara MG, Valle JW.
    J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
    [Abstract] [Full Text] [Related]

  • 3. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M.
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [Abstract] [Full Text] [Related]

  • 4. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M, Heumann T, Goff L, Agarwal R.
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [Abstract] [Full Text] [Related]

  • 5. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
    Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I.
    Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G.
    Cancer Control; 2020 Jun; 27(1):1073274820983013. PubMed ID: 33356500
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN.
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [Abstract] [Full Text] [Related]

  • 12. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G, Mahipal A, John BV.
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systemic treatment options for advanced biliary tract carcinoma.
    Xie C, McGrath NA, Monge Bonilla C, Fu J.
    J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
    [Abstract] [Full Text] [Related]

  • 16. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q.
    Biosci Trends; 2020 Nov 04; 14(5):328-341. PubMed ID: 32830166
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.